At a glance
ClinicalIndex Comparison RecordN/ACompleted· 26 enrolled
Drug / intervention
Ablation with the NanoKnife Low Energy Direct Current (LEDC) Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)
In Brief
A clinical study evaluating Ablation with the NanoKnife Low Energy Direct Current (LEDC) System for Carcinoma, Hepatocellular. Completed, enrolled 26 participants across 6 sites in 4 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Hepatocellular
CountriesFrance, Germany, Italy, Spain
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2010
First PostedMar 2010
Primary CompletionJan 2013
Study CompletionJun 2013
TodayJul 2026
First PostedMar 2, 2010
Enrollment StartFeb 1, 2010
Primary CompletionJan 1, 2013
Study CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 16.3 years ago
Interventions
Ablation with the NanoKnife Low Energy Direct Current (LEDC) Systemdevice
90 pulses of 70 microseconds each in duration will be administered per electrode pair.